Articles amb requisits d'accés públic - Joohyuk SohnMés informació
No estan disponibles en cap lloc: 2
Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer
M Lambertini, M Ceppi, RA Anderson, DA Cameron, M Bruzzone, ...
Journal of the National Comprehensive Cancer Network 21 (1), 33-41. e16, 2023
Requisits: UK Medical Research Council, Government of Italy, AIRC Foundation for Cancer …
Imlunestrant with or without abemaciclib in advanced breast cancer
KL Jhaveri, P Neven, ML Casalnuovo, SB Kim, E Tokunaga, P Aftimos, ...
New England Journal of Medicine, 2024
Requisits: Agence Nationale de la Recherche
Disponibles en algun lloc: 20
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
S Modi, C Saura, T Yamashita, YH Park, SB Kim, K Tamura, F Andre, ...
New England Journal of Medicine 382 (7), 610-621, 2020
Requisits: US National Institutes of Health
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer
S Modi, W Jacot, T Yamashita, J Sohn, M Vidal, E Tokunaga, J Tsurutani, ...
New England Journal of Medicine 387 (1), 9-20, 2022
Requisits: US National Institutes of Health
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
J Baselga, I Bradbury, H Eidtmann, S Di Cosimo, E De Azambuja, C Aura, ...
The Lancet 379 (9816), 633-640, 2012
Requisits: US National Institutes of Health
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE)
SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, ...
Journal of Clinical Oncology 38 (34), 3987-3998, 2020
Requisits: National Institute for Health Research, UK
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind …
SB Kim, R Dent, SA Im, M Espié, S Blau, AR Tan, SJ Isakoff, M Oliveira, ...
The Lancet Oncology 18 (10), 1360-1372, 2017
Requisits: US National Institutes of Health
Capivasertib in hormone receptor–positive advanced breast cancer
NC Turner, M Oliveira, SJ Howell, F Dalenc, J Cortes, HL Gomez Moreno, ...
New England Journal of Medicine 388 (22), 2058-2070, 2023
Requisits: US National Institutes of Health
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ...
Annals of oncology 33 (12), 1250-1268, 2022
Requisits: US National Institutes of Health, National Institute for Health Research, UK
Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced …
YS Lu, SA Im, M Colleoni, F Franke, A Bardia, F Cardoso, N Harbeck, ...
Clinical Cancer Research 28 (5), 851-859, 2022
Requisits: US National Institutes of Health
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
LM Smyth, SA Piha-Paul, HH Won, AM Schram, C Saura, S Loi, J Lu, ...
Cancer discovery 10 (2), 198-213, 2020
Requisits: US National Science Foundation, US National Institutes of Health, V …
Fulvestrant plus vistusertib vs fulvestrant plus everolimus vs fulvestrant alone for women with hormone receptor–positive metastatic breast cancer: the MANTA phase 2 randomized …
P Schmid, M Zaiss, C Harper-Wynne, M Ferreira, S Dubey, S Chan, ...
JAMA oncology 5 (11), 1556-1564, 2019
Requisits: Cancer Research UK, National Institute for Health Research, UK
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
SM Tolaney, M Toi, P Neven, J Sohn, EM Grischke, A Llombart-Cussac, ...
Clinical Cancer Research 28 (8), 1500-1506, 2022
Requisits: US National Institutes of Health
cMET activation and EGFR-directed therapy resistance in triple-negative breast cancer
J Sohn, S Liu, N Parinyanitikul, J Lee, GN Hortobagyi, GB Mills, NT Ueno, ...
Journal of Cancer 5 (9), 745, 2014
Requisits: US National Institutes of Health
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy
GAAM Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F
Ann Oncol, 2013
Requisits: US National Institutes of Health
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
SA Im, B Xu, W Li, M Robson, Q Ouyang, DC Yeh, H Iwata, YH Park, ...
Scientific Reports 10 (1), 8753, 2020
Requisits: US National Institutes of Health
The association between EGFR and cMET expression and phosphorylation and its prognostic implication in patients with breast cancer
YK Chae, DM Gagliato, SG Pai, B Carneiro, N Mohindra, FJ Giles, ...
PLoS One 11 (4), e0152585, 2016
Requisits: US National Institutes of Health
Elevated WBP2 expression in HER2-positive breast cancers correlates with sensitivity to trastuzumab-based neoadjuvant therapy: A retrospective and multicentric study
SA Kang, JS Guan, HJ Tan, T Chu, AA Thike, C Bernado, J Arribas, ...
Clinical Cancer Research 25 (8), 2588-2600, 2019
Requisits: A*Star, Singapore, Government of Spain, National Medical Research Council …
Phase Ia/b Study of Giredestrant±Palbociclib and±Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast …
KL Jhaveri, M Bellet, NC Turner, S Loi, A Bardia, V Boni, J Sohn, ...
Clinical Cancer Research 30 (4), 754-766, 2024
Requisits: US National Institutes of Health
Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer
S Liu, S Li, B Wang, W Liu, M Gagea, H Chen, J Sohn, N Parinyanitikul, ...
Molecular cancer therapeutics 18 (2), 399-412, 2019
Requisits: US National Institutes of Health
Les dades de publicació i de finançament es determinen automàticament per mitjà d'un programa informàtic